BL-B01D1

Overview

BL-B01D1 is a bispecific antibody-drug conjugate (ADC) co-targeting EGFR and ERBB3 (HER3). Simultaneous blockade of both receptors is intended to overcome compensatory signaling through either pathway.

Evidence in the corpus

• In advanced solid tumors (NCT05194982), NPC sub-cohort (n=42): ORR 38%; median PFS 6.8 mo; grade ≥3 TRAE 71% PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.